Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02889523
Recruitment Status : Recruiting
First Posted : September 5, 2016
Last Update Posted : January 6, 2021
Sponsor:
Collaborator:
Epizyme, Inc.
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21.

Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in DLBCL and FL patients :

DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of tazemetostat and 24 months of Rituximab


Condition or disease Intervention/treatment Phase
Lymphoma DLBCL Follicular Lymphoma Drug: Tazemetostat Drug: Rituximab Drug: Cyclophosphamide Drug: Vincristine Drug: Doxorubicin Drug: Prednisolone Phase 1 Phase 2

Detailed Description:

Phase I:

Up to 18 patients will be recruited, using a conventional dose-escalation algorithm (3+3 patients per dose level) to identify the maximum tolerated dose (MTD) which will be deemed the RP2D. Patients will receive 8 cycles of RCHOP every 21 days and tazemetostat every day, starting on day 2 of cycle 1.

4 cohorts are defined, according to dose levels of tazemetostat: 400mg Twice a day (BID) (cohort 1, starting level), 600mg BID (cohort 2), 800mg BID (cohort 3), 200mg BID (cohort -1), depending on the observed toxicities.

Phase II:

Up to 184 patients (122 DLBCL and 62 FL) will be recruited and treated with tazemetostat at the MTD and RCHOP.

Patients will receive 6 cycles of RCHOP every 21 days and tazemetostat at the MTD every day, starting on day 2 of cyle 1, + 2 cycles of Rituximab+tazemetostat. For FL, a maintenance of tazemetostat (6 months) + rituximab (24 months) is expected

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 201 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP
Actual Study Start Date : October 2016
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2026


Arm Intervention/treatment
Experimental: DLBCL cohort

RCHOP + tazemetostat:

- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days

  • Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days
  • Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID
Drug: Tazemetostat
Tablets 200 mg, to be administrated per os
Other Name: EPZ-6438

Drug: Rituximab
375 mg/m²/dose, D1
Other Name: Mabthera

Drug: Cyclophosphamide
750 mg/m²/dose, D1

Drug: Vincristine
1.4 mg/m²/dose (max 2 mg), D1

Drug: Doxorubicin
50 mg/m²/dose, D1

Drug: Prednisolone
40 mg/m2 in the morning D1 to D5

Experimental: FL cohort

RCHOP + tazemetostat:

Induction

  • RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):

    6 cycles, every 21 days

  • Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days
  • Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID

Maintenance

  • Tazemetostat : 6 months (every 8 weeks)
  • Rituximab : 24 months (every 8 weeks)
Drug: Tazemetostat
Tablets 200 mg, to be administrated per os
Other Name: EPZ-6438

Drug: Rituximab
375 mg/m²/dose, D1
Other Name: Mabthera

Drug: Cyclophosphamide
750 mg/m²/dose, D1

Drug: Vincristine
1.4 mg/m²/dose (max 2 mg), D1

Drug: Doxorubicin
50 mg/m²/dose, D1

Drug: Prednisolone
40 mg/m2 in the morning D1 to D5




Primary Outcome Measures :
  1. Phase I : Number of Dose Limiting Toxicities [ Time Frame: 1 cycle (1 cycle is 21 days) ]
    Incidence and severity of treatment-emergent AEs qualifying as protocol defined DLT's in cycle 1 and 2 in order to establish the MTD/RP2D

  2. Phase I : Number of Dose Limiting Toxicities [ Time Frame: 2 cycles (1 cycle is 21 days) ]
    Incidence and severity of treatment-emergent AEs qualifying as protocol defined DLT's in cycle 1 and 2 in order to establish the MTD/RP2D

  3. Phase II - DLBCL Cohort : Complete Response Rate based on local assessment [ Time Frame: 8 cycles (1 cycle is 21 days) ]
    Complete response rate as determined by Cheson International Work Group (IWG) 2014: Lugano Classification (Deauville scale 1-3)

  4. Phase II - FL Cohort : Complete Response Rate based on local assessment [ Time Frame: 8 cycles (1 cycle is 21 days) ]
    Complete response rate as determined by Cheson IWG 2014: Lugano Classification (Deauville scale 1-3)


Secondary Outcome Measures :
  1. Phase I : Serum concentration of CHOP components in presence/absence of Tazemetostat [ Time Frame: Change between baseline - 1 month ]
  2. Phase I : Serum concentration of Tazemetostat and its metabolite (EZH 6930) in presence of CHOP [ Time Frame: Change between baseline - 1 month ]
  3. Phase I : Complete response rate (CRR) by central review using Cheson IWG criteria [ Time Frame: 8 cycles (1 cycle is 21 days) ]
  4. Phase II - DLBCL Cohort : Number of Adverse Events (AE)/Serious Adverse Events (SAE) [ Time Frame: 8 cycles (1 cycle is 21 days) ]
  5. Phase II - DLBCL Cohort : Complete response rate (CRR) by central review using Cheson IWG criteria [ Time Frame: 8 cycles (1 cycle is 21 days) ]
  6. Phase II - DLBCL Cohort : Overall response rate (ORR) by central review [ Time Frame: 52 weeks ]
  7. Phase II - DLBCL Cohort : Overall response rate (ORR) by central review [ Time Frame: 104 weeks ]
  8. Phase II - DLBCL Cohort : progression free survival (PFS) [ Time Frame: 52 weeks ]
  9. Phase II - DLBCL Cohort : progression free survival (PFS) [ Time Frame: 104 weeks ]
  10. Phase II - DLBCL Cohort : duration of response (DR) [ Time Frame: 52 weeks ]
  11. Phase II - DLBCL Cohort : duration of response (DR) [ Time Frame: 104 weeks ]
  12. Phase II - DLBCL Cohort : overall survival (OS) [ Time Frame: 52 weeks ]
  13. Phase II - DLBCL Cohort : overall survival (OS) [ Time Frame: 104 weeks ]
  14. Phase II - DLBCL Cohort : best overall response (BOR) [ Time Frame: 104 weeks ]
  15. Phase II - FL cohort : Number of AE/SAE [ Time Frame: 8 cycles (1 cycle is 21 days) ]
  16. Phase II - FL cohort : Number of AE/SAE [ Time Frame: 13 months ]
  17. Phase II - FL cohort : PET Complete Response Rate (PET-CRR) by central review according to Lugano 2014 criteria [ Time Frame: 8 cycles (1 cycle is 21 days) ]
  18. Phase II - FL cohort : Complete Response Rate (CRR) [ Time Frame: 31 months ]
  19. Phase II - FL cohort : Overall Response Rate (CRR) [ Time Frame: 31 months ]
  20. Phase II - FL cohort : Progression Free Survival (PFS) [ Time Frame: 24 months ]
  21. Phase II - FL cohort : Progression Free Survival (PFS) [ Time Frame: 31 months ]
  22. Phase II - FL cohort : Event Free Survival (EFS) [ Time Frame: 24 months ]
  23. Phase II - FL cohort : Overall Survival (OS) [ Time Frame: 24 months ]
  24. Phase II - FL cohort : Duration of Response (DR) [ Time Frame: 31 months ]
  25. Phase II - FL cohort : Best Overall Response [ Time Frame: 31 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA

    • for Cohort DLBCL ONLY

      • 1-Patients with an untreated DLBCL de novo or transformed from indolent lymphoma (CD 20 positive) with

        • Phase Ib aaIPI ≥ 2
        • Phase II: aaIPI ≥ 1ONLY
      • 2. Age between 60 and 80 years included
    • for Cohort FOLLICULAR ONLY

      • 1-High Tumor Burden (as defined by GELF criteria > 0) frontline follicular lymphoma (FL) with high risk FLIPI 3-5
      • 2. Aged between 18 years and 80 years included
      • 11bis. Females of childbearing potential (FCBP) must agree to use one reliable form of contraception or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 12 months after discontinuation of any study treatments (R-CHOP, tazemetostat, Rituximab)
    • For both Cohorts

      • 1bis- For phase II patients: Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan and/or clinical examination AND a FDG avid disease by PETscan
      • 3.ECOG performance status of 0, 1 or 2 (0 or 1 only for phase Ib)
      • 4.Signed informed consent
      • 5.Life expectancy of ≥ 90 days (3 months) before starting tazemetostat
      • 6.Adequate renal function as calculated by a creatinine clearance > 40 mL/min by local institutional formula
      • 7. Adequate bone marrow function as defined as:

        • ANC ≥ 1500/mm3 (≥ 1.5 X 109/L)
        • Platelets ≥ 75,000/mm3 (≥ 75 X 109/L) without platelet transfusion dependency during the last 7 days
        • Hemoglobin ≥ 9 g/dL (may receive transfusion)
      • 8. Adequate liver function as defined as:

        • Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome
        • Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN (or ≤ 5 X ULN if related to lymphoma involvement)
        • Patients with prior Hepatitis B and C are eligible if, for Hepatitis B detection, surface antigen is negative and/or HBV DNA is undetectable, and for Hepatitis C detection, if HCV RNA is undetectable.
      • 9. Left ventricular ejection fraction (LVEF) ≥ 50% of echocardiography or multiple gated acquisition (MUGA) scan
      • 10. Adequate tissue (surgical excision is recommended) for central pathology review and biological caracterisation (see appendix 11
      • 11. Males with partners of childbearing potential must agree to use reliable forms of contraception during 12 months after last treatment administration
      • 12. Patient covered by any social security system (for France only)
      • 13. Patient who understands and speaks one of the country official languages
  • EXCLUSION CRITERIA

    • for Cohort DLBCL

      ___15-Previous treatment for B cell lymphoma, except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)

    • for Cohort FOLLICULAR ONLY

      • 14bis. Prior therapy for lymphoma including radiotherapy except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)
      • 17-Pregnant or lactating females
    • For both Cohorts

      • 1-Central nervous system or meningeal involvement
      • 2-Contraindication to any drug contained in the chemotherapy regimen
      • 3-Prior treatment with tazemetostat or other inhibitor of EZH2
      • 4-Patients who are undergoing active treatment for another malignancy, exceptions include: A patient who has been disease free for 2 years, or a patient with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible Patients with prior history of myeloid malignancies, including myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia(AML) or prior history of T-LBL/T-ALL are excluded whatever receiving treatment or not and whatever date of diagnosis of these pathologies
      • 5-Patients taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's wort)
      • 6-Patients unwilling to exclude St. John's wort, Seville oranges, grapefruit juice and/or grapefruit from diet
      • 7-Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted within 2 weeks of enrollment)
      • 8-Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impare ability to take tazemetostat
      • 9-Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of tazemetostat or ventricular arrhythmia
      • 10-Not applicable
      • 11-Active uncontrolled infection requiring systemic therapy
      • 12-Congenital immunodeficiency or known HIV (human immunodeficiency virus infection)
      • 13-Any other major illness, that in the investigator's judgement, will substantially increase the risk associated with the patient's participation in the study
      • 14-Patients who have undergone a solid organ transplant
      • 16-Treatment with any investigational drug or device within 30 days before planned first cycle of chemotherapy
      • 18-Person deprived of his/her liberty by a judicial or administrative decision
      • 19-Adult person under legal protection
      • 20-Person hospitalized without consent
      • 21-Adult person unabled to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02889523


Contacts
Layout table for location contacts
Contact: Chloe Gourc-Berthod +33 (04) 72 66 93 33 chloe.gourc-berthod@lysarc.org

Locations
Show Show 31 study locations
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Epizyme, Inc.
Investigators
Layout table for investigator information
Study Chair: Vincent Ribrag, MD Institut Gustave Roussy Cancer Campus Grand Paris
Study Chair: Clémentine Sarkozy, MD Institut Gustave Roussy Cancer Campus Grand Paris
Study Chair: Franck Morshhauser, Pr Centre Régional Hospitalier de Lille
Study Chair: Loic Ysebaert, MD IUCT Oncopole de Toulouse
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier: NCT02889523    
Other Study ID Numbers: Epi-RCHOP
First Posted: September 5, 2016    Key Record Dates
Last Update Posted: January 6, 2021
Last Verified: January 2021
Keywords provided by The Lymphoma Academic Research Organisation:
Front line therapy
Age-adjusted International Prognostic Index (aa-IPI) >1
60 to 80 years
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Prednisolone
Cyclophosphamide
Rituximab
Doxorubicin
Vincristine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Phytogenic
Tubulin Modulators